Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Rámon Polo

Key Takeaway: Dr. Ramón Polo has joined Aligos as the Senior Vice President, Head of Global Regulatory Affairs. With a robust background in regulatory strategies across various therapeutic areas, including infectious diseases, he previously held significant roles at Shionogi and Johnson & Johnson. Dr. Polo's expertise is anticipated to strengthen Aligos' regulatory framework.
Price reaction · baseline $12.0025 (2024-08-15 close) · hit pre-market · 1 other ALGS headline(s) in the window, move may be shared
day 0 close
+9.4%
day 1 · peak
+18.7%
day 3
+14.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Polo brings extensive regulatory experience to Aligos.
  • His leadership in global regulatory affairs is expected to enhance Aligos' strategies.
  • He has a strong background in managing regulatory challenges during the COVID-19 pandemic.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

Dr. Rámon Polo, PharmD, PhD, MBA, joined Aligos in 2025 as the Senior Vice President, Head of Global Regulatory Affairs. Dr. Polo’s diverse expertise includes leading and overseeing development teams, pharmacovigilance programs and regulatory strategies. He joins Aligos from Shionogi Inc., where he served as the Senior Vice President, Head of Global Regulatory Affairs, and focused on regulatory strategies for a number of different Therapeutic Areas, including infectious diseases. Previously, Dr. Polo was the Vice President, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs at Johnson & Johnson, where he played a key role in navigating the scientific, regulatory and global rollout challenges of the largest health crisis in a century as part of Johnson & Johnson’s core team for the COVID-19 vaccine. Prior to this, Dr. Polo led the development strategy of treatments for influenza, RSV and hepatitis C at Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Polo received his PharmD, Master of Science and Ph.D. in Clinical Biochemistry from the Complutense University of Madrid in Spain. He obtained his Global MBA from the IESE Business School, University of Navarra, and attended the Program for Management Development at Harvard Business School.

Frequently Asked Questions

What position did Dr. Ramón Polo take at Aligos?

Dr. Ramón Polo joined Aligos as the Senior Vice President, Head of Global Regulatory Affairs.

What was Dr. Polo's role at Johnson & Johnson?

He served as Vice President, Head of Infectious Diseases and played a key role in the COVID-19 vaccine rollout.

Where did Dr. Polo work before joining Aligos?

He was the Senior Vice President at Shionogi Inc., overseeing global regulatory affairs.

What degrees does Dr. Polo hold?

Dr. Polo has a PharmD, PhD in Clinical Biochemistry, and a Global MBA.

Last updated: Aug 16, 2024